Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01109004 · ClinicalTrials.gov registry record · Phase 3
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
A Phase 3 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 3
- Development phase
- 758
- Enrollment target
NCT01109004 is a Phase 3 study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 758 participants.
The verdict
NCT01109004, a Phase 3 study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 758 participants
- Enrollment target
Study Summary
The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus maintenance therapy versus the strategy of single autologous transplant plus consolidation therapy with lenalidomide, bortezomib and dexamethasone (RVD) followed by maintenance therapy or single autologous transplant plus maintenance therapy as part of upfront treatment of multiple myeloma (MM). Lenalidomide will be used as maintenance therapy for three years in all arms.
Interventions
- DRUG Lenalidomide
- DRUG lenalidomide, bortezomib and dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 758 participants |
| Start Date | 2010-05 |
| Est. Completion | 2018-03-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01109004
The ClinicalTrials.gov registry entry for NCT01109004 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 758 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT01109004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01109004 about?
NCT01109004 is a clinical study titled "Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)". The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus maintenance therapy versus the strategy of single autologous transplant plus consolidation therapy with lenalidomide, bortezomib and dexamethasone (RVD) followed by maintenance therapy or single autologous ...
What is the current status of trial NCT01109004?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 758 participants. The study started on 2010-05. Estimated completion is 2018-03-03.
What interventions are being tested in trial NCT01109004?
The interventions under investigation include: Lenalidomide (DRUG), lenalidomide, bortezomib and dexamethasone (DRUG).
Who is sponsoring clinical trial NCT01109004?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.